title: New biomarkers of Maillard reaction damage to proteins.
abstract: The amount of advanced glycation end-products (AGE) in tissue proteins increases in diabetes mellitus, and the concentration of a subclass of AGEs, known as glycoxidation products, also increases with chronological age in proteins. The rate of accumulation of glycoxidation products is accelerated in diabetes and age-adjusted concentrations of two glycoxidation products, N epsilon-(carboxymethyl)lysine (CML) and pentosidine, correlate with the severity of complication in diabetic patients. Although AGEs and glycoxidation products are implicated in the development of diabetic complications, these compounds are present at only trace concentrations in tissue proteins and account for only a fraction of the chemical modifications in AGE proteins prepared in vitro. The future of the AGE hypothesis depends on the chemical characterization of a significant fraction of the total AGEs in tissue proteins, a quantitative assessment of their effects on protein structure and function, and an assessment of their role as mediators of biological responses. In this manuscript we describe recent work leading to characterization of new AGEs and glycoxidation products. These compounds include: (1) the imidazolone adduct formed by reaction of 3-deoxyglucosone with arginine residues in protein; (2) N epsilon-(carboxyethyl)lysine, an analogue of CML formed on reaction of methylglyoxal with lysine; (3) glyoxal-lysine dimer; and (4) methyl-glyoxal-lysine dimer, which are imidazolium crosslinks formed by reaction of glyoxal or methylglyoxal with lysine residues in protein. The presence of 3-deoxyglucosone, methylglyoxal and glyoxal in vivo and the formation of the above AGEs in model carbonyl-amine reaction systems suggests that these AGEs are also formed in vivo and contribute to tissue damage resulting from the Maillard reaction.
authors.affiliation: Department of Chemistry and Biochemistry, University of South Carolina, Columbia 29208, USA.
authors.forename: K J
authors.initials: KJ
authors.lastname: Wells-Knecht
authors.forename: E
authors.initials: E
authors.lastname: Brinkmann
authors.forename: M C
authors.initials: MC
authors.lastname: Wells-Knecht
authors.forename: J E
authors.initials: JE
authors.lastname: Litchfield
authors.forename: M U
authors.initials: MU
authors.lastname: Ahmed
authors.forename: S
authors.initials: S
authors.lastname: Reddy
authors.forename: D V
authors.initials: DV
authors.lastname: Zyzak
authors.forename: S R
authors.initials: SR
authors.lastname: Thorpe
authors.forename: J W
authors.initials: JW
authors.lastname: Baynes
mesh_terms: D000375:Aging / Q000378:metabolism; D001120:Arginine / Q000031:analogs & derivatives / Q000378:metabolism; D015415:Biomarkers; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000737:chemistry / Q000378:metabolism*; D006031:Glycosylation; D006801:Humans; D008239:Lysine / Q000031:analogs & derivatives / Q000378:metabolism; D015416:Maillard Reaction; D015394:Molecular Structure; D009646:Norleucine / Q000031:analogs & derivatives / Q000378:metabolism; D010084:Oxidation-Reduction; D011506:Proteins / Q000378:metabolism*; D011758:Pyrroles / Q000378:metabolism
chemical_list: D015415:Biomarkers; D017127:Glycation End Products, Advanced; D011506:Proteins; D011758:Pyrroles; C048496:N(6)-carboxymethyllysine; C059571:2-formyl-5-(hydroxymethyl)pyrrole-1-norleucine; D009646:Norleucine; D001120:Arginine; C062187:pentosidine; D008239:Lysine